Brief: Lipocine Announces First Cohort Dosed In Pivotal Study Of LPCN 1154
25/03/2024 10:26
March 25 (Reuters) - Lipocine Inc LPCN.O :
* LIPOCINE INC - ANNOUNCES FIRST COHORT DOSED IN PIVOTAL
STUDY OF
LPCN 1154
* LIPOCINE INC - ANTICIPATES TOPLINE RESULTS FROM THIS
CROSSOVER
PIVOTAL STUDY LATE IN Q2 OF 2024
Source text for Eikon: ID:n0001493152-24-011053
Further company coverage: LPCN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lipocine
See all newsUS STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
U.S. STOCKS ON THE MOVE-Hecla Mining, XPO, Lipocine
Lipocine surges after Canada approves co's testosterone replacement therapy
Brief: Lipocine Announces Health Canada Approval Of Tlando For Testosterone Replacement Therapy